IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

02/20/2026

In Alzheimer’s, progress is shaped not only by science, but also by the people who stand beside their loved ones every day, offering patience, stability, and support through change.

On National Caregiver Day, we recognize their presence and the important role they play in the Alzheimer’s journey, while continuing our commitment to advancing science with empathy and responsibility.

02/18/2026

A Notice of Allowance has been issued by the Canadian Intellectual Property Office covering the proprietary composition underlying IGC-AD1.

Patent Application No. 3,095,729, titled “Method and Composition for Treating CNS Disorders,” secures composition protection across key North American jurisdictions. Approximately 70% of planned enrollment in the Phase 2 CALMA trial has been completed. The Company believes that strengthening composition protection at this stage enhances both the durability and commercial positioning of IGC-AD1 as the program advances.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-secures-north-american-133000184.html

02/18/2026

Today at 1:00 p.m. ET, IGC Pharma’s CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets.

Topics will include Phase 2 CALMA trial updates and advancements across the Company’s broader pipeline of disease-modifying Alzheimer’s candidates.

Register to attend: https://pr.report/ime7

02/14/2026

Alzheimer’s disease can reshape relationships in profound ways.

Spouse caregivers remind us that commitment can endure, even as circumstances change. Their strength often shows up quietly, through daily acts of presence, patience, and resilience.

At IGC Pharma, we recognize the dedication of spouse caregivers whose journeys often unfold away from the spotlight. Elena’s story, shared in Alzheimer’s Caregivers, offers a meaningful glimpse into the lived reality of caring for a partner through this disease.

Read the full book:https://igcpharma.com/wp-content/uploads/2025/12/Alzheimers_Caregivers-English-_Version.pdf

02/13/2026

IGC Pharma’s CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026 at 1:00 p.m. ET.

The discussion will include enrollment momentum and regulatory developments in the Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease, as well as progress across the Company’s broader pipeline of disease-modifying Alzheimer’s candidates.

Register here: https://pr.report/ime7

02/11/2026

On the International Day of Women and Girls in Science, we celebrate the women scientists at IGC Pharma whose work is guided by curiosity, discipline, and long-term commitment

Through their dedication, they help advance understanding of Alzheimer’s disease by asking thoughtful questions, building strong scientific evidence, and tackling complex challenges with rigor and purpose

Today, we recognize their essential role in shaping the future of Alzheimer’s research and scientific innovation

02/11/2026

Alliance Global Partners has published an updated equity research report covering IGC Pharma.

All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy or completeness of any analyst report and undertakes no obligation to update or correct the information.

Read the full report: jmolloy@allianceg.com&source=mail" rel="ugc" target="_blank">https://europac.bluematrix.com/sellside/EmailDocViewer?encrypt=8f03e8a2-b153-4f30-872b-2106a885e61f&mime=pdf&co=europac&id=jmolloy@allianceg.com&source=mail

02/10/2026

The Phase 2 CALMA clinical trial continues to advance with the addition of Grupo de Neurociencias de Antioquia as a new clinical site in Colombia.

With approximately 70% of planned enrollment completed, IGC Pharma expects to complete enrollment by mid-2026. The randomized, double-blind, placebo-controlled study continues to progress across a clinical network of 23 active sites in 26 locations, evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-expands-phase-2-133000854.html

02/05/2026

Alzheimer’s research is about more than innovation, it’s about responsibility.

At IGC Pharma, we believe that how research is done matters. Taking time, making thoughtful decisions, and handling data with care helps build trust with patients, families, and the communities affected by Alzheimer’s.

These values guide our work and remind us why integrity and empathy are essential at every step.

02/03/2026

IGC Pharma has reached a key enrollment milestone in its Phase 2 clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.

With enrollment progressing across approximately 23 active sites in 26 locations, the study continues to advance through its clinical network. Enrollment is expected to be completed by mid-2026.

IGC-AD1 is an investigational, cannabinoid-based therapy being evaluated in a randomized, double-blind, placebo-controlled clinical trial designed to assess safety and efficacy in agitation associated with Alzheimer’s disease.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-reaches-70-enrollment-133000929.html

01/26/2026

Patients and caregivers are at the heart of everything we do.

Every journey with Alzheimer’s is deeply personal. Behind each diagnosis is a family learning, adapting, and caring with strength and compassion.

At IGC Pharma, our work is guided by respect for patients, support for caregivers, and a shared commitment to doing better, together.

01/23/2026

IGC Pharma adds Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in its Phase 2 CALMA clinical trial.

This new site conducts research across a broad range of central nervous system disorders, including Alzheimer’s disease and mild cognitive impairment, and supports IGC Pharma’s focus on high-quality data generation, efficient trial ex*****on, and patient engagement.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-expands-phase-2-140000971.html
hashtag hashtag hashtag hashtag

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.